Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
RCKT · Why this verdict
Why Rocket Pharmaceuticals (RCKT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.3/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The stock offers extreme asymmetric upside per the engine — 112.7% to the analyst-target take-profit against a 15% downside stop — reflecting a binary biotech setup where positive trial or regulatory news could re-rate shares sharply higher. Estimated upside | The stock should close at least half the gap to the $8.17 analyst-target take-profit over the next 12 months if the bull case plays out. | →Stable |
| CounterBinary biotech upside targets are frequently never realized if a clinical or regulatory catalyst disappoints, and the stock could instead grind toward the downside stop. | ||
Rocket's business quality sits below the engine's floor — it is cash-burning with negative free cash flow and no competitive moat — meaning the upside case depends entirely on clinical success rather than current fundamentals. Quality breakdown | Cash burn should not accelerate further, and the company should maintain enough runway through its next major catalyst without a dilutive raise. | →Stable |
| CounterContinued cash burn without a moat means any clinical setback could force a highly dilutive capital raise, permanently impairing per-share upside even if the science eventually works. | ||
Even though the recent rally is being read by the engine as a recovery attempt after a death cross, the stock shows late-cycle distribution risk: RSI at 84 with a flattening-to-negative 200-day moving average slope, suggesting the rally may be running out of steam technically even as it accumulates volume. Momentum breakdown | The 200-day moving average slope should turn positive and RSI should cool from overbought levels without a sharp price reversal. | →Stable |
| CounterRising volume alongside overbought RSI can also mark genuine accumulation ahead of a catalyst, not just distribution, particularly in event-driven biotech names. | ||
High short interest of 25% is flagged by the engine as justified given the quality concerns, indicating a meaningful bear thesis is already expressed in the market that could pressure the stock if the recovery narrative falters. Risk breakdown | Short interest should decline from 25% as the bear thesis is disproven, rather than increase further. | →Stable |
| CounterHigh short interest can also fuel a short squeeze on positive news, which would argue for upside rather than against the thesis. | ||
Recent insider transactions carry a bearish signal, with $275,035 in net selling over the last 90 days, a modest but directionally negative data point against the bullish asymmetry case. Insider transaction read | Insider signal should shift to neutral or bullish if those closest to the company still see meaningful upside at current levels. | →Stable |
| CounterAt only 0.066% of market cap, this sale is too small to carry real information value and may simply reflect routine diversification. | ||
The stock offers extreme asymmetric upside per the engine — 112.7% to the analyst-target take-profit against a 15% downside stop — reflecting a binary biotech setup where positive trial or regulatory news could re-rate shares sharply higher.
→StableEstimated upside
- Expectation
- The stock should close at least half the gap to the $8.17 analyst-target take-profit over the next 12 months if the bull case plays out.
CounterBinary biotech upside targets are frequently never realized if a clinical or regulatory catalyst disappoints, and the stock could instead grind toward the downside stop.
Rocket's business quality sits below the engine's floor — it is cash-burning with negative free cash flow and no competitive moat — meaning the upside case depends entirely on clinical success rather than current fundamentals.
→StableQuality breakdown
- Expectation
- Cash burn should not accelerate further, and the company should maintain enough runway through its next major catalyst without a dilutive raise.
CounterContinued cash burn without a moat means any clinical setback could force a highly dilutive capital raise, permanently impairing per-share upside even if the science eventually works.
Even though the recent rally is being read by the engine as a recovery attempt after a death cross, the stock shows late-cycle distribution risk: RSI at 84 with a flattening-to-negative 200-day moving average slope, suggesting the rally may be running out of steam technically even as it accumulates volume.
→StableMomentum breakdown
- Expectation
- The 200-day moving average slope should turn positive and RSI should cool from overbought levels without a sharp price reversal.
CounterRising volume alongside overbought RSI can also mark genuine accumulation ahead of a catalyst, not just distribution, particularly in event-driven biotech names.
High short interest of 25% is flagged by the engine as justified given the quality concerns, indicating a meaningful bear thesis is already expressed in the market that could pressure the stock if the recovery narrative falters.
→StableRisk breakdown
- Expectation
- Short interest should decline from 25% as the bear thesis is disproven, rather than increase further.
CounterHigh short interest can also fuel a short squeeze on positive news, which would argue for upside rather than against the thesis.
Recent insider transactions carry a bearish signal, with $275,035 in net selling over the last 90 days, a modest but directionally negative data point against the bullish asymmetry case.
→StableInsider transaction read
- Expectation
- Insider signal should shift to neutral or bullish if those closest to the company still see meaningful upside at current levels.
CounterAt only 0.066% of market cap, this sale is too small to carry real information value and may simply reflect routine diversification.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Rocket Pharmaceuticals offers extreme asymmetric upside per the engine's target-based framework, but that upside rests entirely on a binary clinical outcome, with cash-burning fundamentals, a stretched technical setup, and elevated short interest all working against the thesis.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 6.9 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.6 |
| MACD | 9.0 |
| OBV | 10.0 |
| MA position | 7.5 |
| Volume | 5.0 |
- ▸Overbought (RSI 88)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat/negative + RSI 88 (late-cycle distribution risk)
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 121%
Insider
5.5/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 10.0 |
- ▸Modest insider selling — $275,035 (0.063% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 1.6 |
| growth rank | 5.0 |
Technical
2.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.2 |
| support resistance | 0.3 |
| 52w position | 5.6 |
Risk (lower is worse)
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.0 |
| days to cover | 1.3 |
| volatility | 0.0 |
| put call | 6.7 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 10.0 |
| debt equity | 9.6 |
- ▸High short interest justified: 25%
- ▸High IV: 117%
- ▸Above max pain $2
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.4/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 4.8 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:7.0>=5.5
- ASYMMETRY:6.2>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:30d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- DEATH_CROSS:momentum=7.0>=5.0 recovering
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
6.17
Upside
+92.6%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 88
EdgeInst Constrain — Small cap ($0.4B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 9.0, Momentum at 7.0, and Sentiment at 6.6; the weakest are Quality at 1.8, Technical at 2.0, and Risk (lower is worse) at 4.0. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 6.17 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Extreme Asymmetric Upside
Trip ifPrice falls below the $3.57 stop-loss level, a decline of more than 7% from current levels.
- P2Cash Burn Quality Concern
Trip ifThe company announces an equity raise diluting shares outstanding by more than 15%.
- P3Late Cycle Distribution Risk
Trip ifRSI falls below 30 within 3 months, signaling a reversal from the current overbought 84 reading.
- P4High Short Interest Risk
Trip ifShort interest rises above 35% of float from the current 25%.
- P5Recent Insider Selling
Trip ifNet insider selling exceeds $1 million over a rolling 90-day period.